Checkpoint Therapeutics
New York
New York
United States
61 articles with Checkpoint Therapeutics
-
Checkpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
3/2/2023
Checkpoint Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing the Biologics License Application (“BLA”) for cosibelimab.
-
Checkpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
1/17/2023
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities’ 3rd Annual Oncology Conference, taking place on Wednesday, January 18, 2023, at 11:00 a.m. EST.
-
Checkpoint Therapeutics Announces Reverse Stock Split - December 05, 2022
12/5/2022
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock.
-
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
11/8/2022
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2022, and recent corporate highlights.
-
Checkpoint Therapeutics to Participate in Two Upcoming September 2022 Investor Conferences
9/8/2022
Checkpoint Therapeutics, Inc. announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences.
-
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8/12/2022
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2022, and recent corporate highlights.
-
Checkpoint Therapeutics announced that its checkpoint inhibitor cosibelimab is showing positive objective response rate data in patients with locally advanced cutaneous squamous cell carcinoma.
-
Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
6/16/2022
Objective response rate of 54.8% in patients with locally advanced cSCC, a potential 2nd indication for cosibelimab.
-
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
6/6/2022
Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the presentation of data from its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cSCC) during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Checkpoint Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
5/19/2022
Checkpoint Therapeutics, Inc., will present a company overview at the H.C. Wainwright Global Investment Conference, on Wednesday, May 25, 2022, at 3:00 p.m. ET.
-
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory
5/13/2022
Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has received Pediatric Investigation Plan (PIP) product-specific waivers from the European Medicines Agency (EMA) and the U.K. Medicines & Healthcare products Regulatory Agency (MHRA) for cosibelimab in cutaneous squamous cell carcinoma (cSCC).
-
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
5/12/2022
Checkpoint Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2022 and recent corporate highlights.
-
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the results of its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cSCC) have been selected for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
4/4/2022
Checkpoint Therapeutics, Inc. today announced that members of Checkpoint’s management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022.
-
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
3/28/2022
Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference
1/25/2022
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Justin Walsh, Equity Research Analyst (Biotechnology), at the B. Riley Securities’ Virtual Oncology Conference.
-
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
1/25/2022
Checkpoint Therapeutics, Inc. today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody.
-
Clinical Catch-Up: December 6-10
12/13/2021
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look. -
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
12/8/2021
Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC).